Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12261482 | 0.75 | TRPM8 (0.38) | ALDH1A1EGFRGAAMAPTTRPM8 | |
| SCHEMBL18246069 | 0.75 | APLNR (0.38) | APLNRALDH1A1ADRB3KMT2ANPC1 | |
| SCHEMBL6050416 | 0.71 | ALDH1A1 (0.40) | ALDH1A1EGFRGAAMAPTTSHR | |
| SCHEMBL13887438 | 0.69 | — | — | |
| SCHEMBL18245582 | 0.69 | APLNR (0.38) | APLNRMAPTADRB3NPC1RAB9A | |
| SCHEMBL11088625 | 0.66 | MAPT (0.40) | ALDH1A1EGFRGAAMAPTKMT2A | |
| SCHEMBL18246742 | 0.66 | APLNR (0.36) | APLNRADRB3 | |
| Hydrochloric Acid SCHEMBL20502520 | 0.66 | MAPT (0.41) | ALDH1A1EGFRGAAMAPTADRA1A | |
| SCHEMBL9527392 | 0.66 | TRPM8 (0.36) | ALDH1A1EGFRGAAMAPTKMT2A | |
| SCHEMBL12261480 | 0.65 | TRPM8 (0.38) | ALDH1A1EGFRGAAMAPTADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190100510-A1 | BROMOTRIAZOLE INTERMEDIATES | AMGEN INC. (US) | 2019-04-04 | — | — | US | disclosed |
| US-10221162-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180319773-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2018-11-08 | — | — | US | disclosed |
| US-10058550-B2 | Methods of treating heart failure | AMGEN INC. (US) | 2018-08-28 | — | — | US | disclosed |
| US-9868721-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9845310-B2 | Intermediates for preparing triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170281625-A1 | METHODS OF TREATING HEART FAILURE | AMGEN INC. | 2017-10-05 | — | — | US | disclosed |
| US-9751864-B2 | Methods for preparing triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9745286-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9656997-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656998-B2 | Intermediates for preparing triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9573936-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20170044131-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170042897-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170042872-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170042871-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170035744-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170037026-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-09 | — | — | US | disclosed |
| US-20160340336-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170042871-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | APLNR 4/4885ALDH1A1 1773/4885EGFR 2967/4885 |
| US-20180319773-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | APLNR 4/4885ALDH1A1 1773/4885EGFR 2967/4885 |
| US-20170044131-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | APLNR 4/4885ALDH1A1 1773/4885EGFR 2967/4885 |
| US-20190100510-A1 | BROMOTRIAZOLE INTERMEDIATES | APH1A, BRDT, APH1B | APLNR 296/4885ALDH1A1 2621/4885EGFR 1671/4885 |
| US-20170042872-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | APLNR 4/4885ALDH1A1 1773/4885EGFR 2967/4885 |
| US-10058550-B2 | Methods of treating heart failure | FABP3, TNNI3, APLNR | APLNR 3/4885ALDH1A1 3046/4885EGFR 3814/4885 |
| US-20170037026-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | APLNR 4/4885ALDH1A1 1773/4885EGFR 2967/4885 |
| US-10221162-B2 | Triazole agonists of the APJ receptor | TBXA2R, AGTR1, AGTR2 | APLNR 4/4885ALDH1A1 1773/4885EGFR 2967/4885 |
| US-20170281625-A1 | METHODS OF TREATING HEART FAILURE | FABP3, TNNI3, APLNR | APLNR 3/4885ALDH1A1 3046/4885EGFR 3814/4885 |
| US-20170042897-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | APLNR 4/4885ALDH1A1 1773/4885EGFR 2967/4885 |
| US-20160340336-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | APLNR 4/4885ALDH1A1 1773/4885EGFR 2967/4885 |
| US-20170035744-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | APLNR 4/4885ALDH1A1 1773/4885EGFR 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.